311 related articles for article (PubMed ID: 28753677)
1. Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
Chao TK; Huang TS; Liao YP; Huang RL; Su PH; Shen HY; Lai HC; Wang YC
PLoS One; 2017; 12(7):e0182166. PubMed ID: 28753677
[TBL] [Abstract][Full Text] [Related]
2. Specific Pyruvate Kinase M2 Inhibitor, Compound 3K, Induces Autophagic Cell Death through Disruption of the Glycolysis Pathway in Ovarian Cancer Cells.
Park JH; Kundu A; Lee SH; Jiang C; Lee SH; Kim YS; Kyung SY; Park SH; Kim HS
Int J Biol Sci; 2021; 17(8):1895-1908. PubMed ID: 34131394
[TBL] [Abstract][Full Text] [Related]
3. Shikonin Inhibits Tumor Growth in Mice by Suppressing Pyruvate Kinase M2-mediated Aerobic Glycolysis.
Zhao X; Zhu Y; Hu J; Jiang L; Li L; Jia S; Zen K
Sci Rep; 2018 Sep; 8(1):14517. PubMed ID: 30266938
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of Pyruvate Kinase M2 Markedly Reduces Chemoresistance of Advanced Bladder Cancer to Cisplatin.
Wang X; Zhang F; Wu XR
Sci Rep; 2017 Apr; 7():45983. PubMed ID: 28378811
[TBL] [Abstract][Full Text] [Related]
5. Shikonin and its analogs inhibit cancer cell glycolysis by targeting tumor pyruvate kinase-M2.
Chen J; Xie J; Jiang Z; Wang B; Wang Y; Hu X
Oncogene; 2011 Oct; 30(42):4297-306. PubMed ID: 21516121
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel naphthoquinone derivatives as inhibitors of the tumor cell specific M2 isoform of pyruvate kinase.
Ning X; Qi H; Li R; Li Y; Jin Y; McNutt MA; Liu J; Yin Y
Eur J Med Chem; 2017 Sep; 138():343-352. PubMed ID: 28688274
[TBL] [Abstract][Full Text] [Related]
7. CHIP/Stub1 regulates the Warburg effect by promoting degradation of PKM2 in ovarian carcinoma.
Shang Y; He J; Wang Y; Feng Q; Zhang Y; Guo J; Li J; Li S; Wang Y; Yan G; Ren F; Shi Y; Xu J; Zeps N; Zhai Y; He D; Chang Z
Oncogene; 2017 Jul; 36(29):4191-4200. PubMed ID: 28346425
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and antitumor activity of novel 2, 3-didithiocarbamate substituted naphthoquinones as inhibitors of pyruvate kinase M2 isoform.
Ning X; Qi H; Li R; Jin Y; McNutt MA; Yin Y
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):126-129. PubMed ID: 29185365
[TBL] [Abstract][Full Text] [Related]
9. Transcription factor LHX9 (LIM Homeobox 9) enhances pyruvate kinase PKM2 activity to induce glycolytic metabolic reprogramming in cancer stem cells, promoting gastric cancer progression.
Zhao H; Jiang R; Feng Z; Wang X; Zhang C
J Transl Med; 2023 Nov; 21(1):833. PubMed ID: 37980488
[TBL] [Abstract][Full Text] [Related]
10. OSU-A9 induced-reactive oxygen species cause cytotoxicity in duodenal and gastric cancer cells by decreasing phosphorylated nuclear pyruvate kinase M2 protein levels.
Chiu CF; Weng JR; Lee SL; Wu CY; Chu PC; Shan YS; Yang HR; Bai LY
Biochem Pharmacol; 2020 Apr; 174():113811. PubMed ID: 31954719
[TBL] [Abstract][Full Text] [Related]
11. Lapachol inhibits glycolysis in cancer cells by targeting pyruvate kinase M2.
Shankar Babu M; Mahanta S; Lakhter AJ; Hato T; Paul S; Naidu SR
PLoS One; 2018; 13(2):e0191419. PubMed ID: 29394289
[TBL] [Abstract][Full Text] [Related]
12. Shikonin inhibited glycolysis and sensitized cisplatin treatment in non-small cell lung cancer cells via the exosomal pyruvate kinase M2 pathway.
Dai Y; Liu Y; Li J; Jin M; Yang H; Huang G
Bioengineered; 2022 May; 13(5):13906-13918. PubMed ID: 35706397
[TBL] [Abstract][Full Text] [Related]
13. Pyruvate kinase M2: multiple faces for conferring benefits on cancer cells.
Tamada M; Suematsu M; Saya H
Clin Cancer Res; 2012 Oct; 18(20):5554-61. PubMed ID: 23071357
[TBL] [Abstract][Full Text] [Related]
14. Aberrant overexpression of pyruvate kinase M2 is associated with aggressive tumor features and the BRAF mutation in papillary thyroid cancer.
Feng C; Gao Y; Wang C; Yu X; Zhang W; Guan H; Shan Z; Teng W
J Clin Endocrinol Metab; 2013 Sep; 98(9):E1524-33. PubMed ID: 23846818
[TBL] [Abstract][Full Text] [Related]
15. Tumor M2-PK: A novel urine marker of bladder cancer.
Liu W; Woolbright BL; Pirani K; Didde R; Abbott E; Kaushik G; Martin P; Hamilton-Reeves J; Taylor JA; Holzbeierlein JM; Anant S; Lee EK
PLoS One; 2019; 14(6):e0218737. PubMed ID: 31246990
[TBL] [Abstract][Full Text] [Related]
16. 2'-hydroxycinnamaldehyde inhibits cancer cell proliferation and tumor growth by targeting the pyruvate kinase M2.
Yoon YJ; Kim YH; Jin Y; Chi SW; Moon JH; Han DC; Kwon BM
Cancer Lett; 2018 Oct; 434():42-55. PubMed ID: 30009856
[TBL] [Abstract][Full Text] [Related]
17. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1α to overcome apoptosis in a refractory HCC cell line.
Yang W; Liu J; Hou L; Chen Q; Liu Y
Life Sci; 2021 Jan; 265():118796. PubMed ID: 33220292
[TBL] [Abstract][Full Text] [Related]
18. Targeting stromal-induced pyruvate kinase M2 nuclear translocation impairs oxphos and prostate cancer metastatic spread.
Giannoni E; Taddei ML; Morandi A; Comito G; Calvani M; Bianchini F; Richichi B; Raugei G; Wong N; Tang D; Chiarugi P
Oncotarget; 2015 Sep; 6(27):24061-74. PubMed ID: 26183399
[TBL] [Abstract][Full Text] [Related]
19. Expression of pyruvate kinase M2 in human colorectal cancer and its prognostic value.
Cui R; Shi XY
Int J Clin Exp Pathol; 2015; 8(9):11393-9. PubMed ID: 26617865
[TBL] [Abstract][Full Text] [Related]
20. Identification of small molecule inhibitors of pyruvate kinase M2.
Vander Heiden MG; Christofk HR; Schuman E; Subtelny AO; Sharfi H; Harlow EE; Xian J; Cantley LC
Biochem Pharmacol; 2010 Apr; 79(8):1118-24. PubMed ID: 20005212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
